Pazopanib-laden lipid based nanovesicular delivery with augmented oral bioavailability and therapeutic efficacy against non-small cell lung cancer

This publication has 67 references indexed in Scilit:

• New views on cellular uptake and trafficking of manufactured nanoparticles
  Journal of The Royal Society Interface, 2013
• Pazopanib: Clinical development of a potent anti-angiogenic drug
  Critical Reviews in Oncology/Hematology, 2011
• (Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor
  The Oncologist, 2010
• Use of Placket–Burman Statistical Design to Study Effect of Formulation Variables on the Release of Drug from Hot Melt Sustained Release Extrudates
  AAPS PharmSciTech, 2010
• Development and optimization of solid lipid nanoparticles of amikacin by central composite design
  Journal of Liposome Research, 2010
• Development and Statistical Optimization of Solid Lipid Nanoparticles of Simvastatin by Using 23 Full-Factorial Design
  AAPS PharmSciTech, 2010
• Formulation and optimization of solid lipid nanoparticles of buspirone HCl for enhancement of its oral bioavailability
  Journal of Liposome Research, 2009
• Phase I Trial of Pazopanib in Patients with Advanced Cancer
  Clinical Cancer Research, 2009
• Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery
  Nanomedicine: Nanotechnology, Biology and Medicine, 2009
• Encapsulating Vesicles and Colloids from Cochleate Cylinders
  Langmuir, 2003